CAPVAXIVE 65 ug/.5mL
Pneumococcal 21-valent Conjugate Vaccine · INJECTION, SOLUTION · Merck Sharp & Dohme LLC
CAPVAXIVE is a injection, solution containing pneumococcal 21-valent conjugate vaccine at 65 ug/.5mL, taken intramuscular. Manufactured by Merck Sharp & Dohme LLC.
Key Facts
- Brand Name
- CAPVAXIVE
- Generic Name
- Pneumococcal 21-valent Conjugate Vaccine
- NDC Code (Product)
0006-4347- Manufacturer
- Merck Sharp & Dohme LLC
- Strength
- 65 ug/.5mL
- Dosage Form
- INJECTION, SOLUTION
- Route
- INTRAMUSCULAR
- Marketing Status
- Application #
- BLA125814
- Marketing Start
- 06/17/2024
Recall History
No Recall HistoryFrequently Asked Questions
What is CAPVAXIVE used for?
CAPVAXIVE contains Pneumococcal 21-valent Conjugate Vaccine. It is a injection, solution taken intramuscular. Consult your doctor for specific uses.
Is CAPVAXIVE a controlled substance?
CAPVAXIVE is not classified as a controlled substance by the DEA.
What is the generic name for CAPVAXIVE?
The generic name for CAPVAXIVE is Pneumococcal 21-valent Conjugate Vaccine. There are no other listed brand versions of Pneumococcal 21-valent Conjugate Vaccine.
What is the NDC code for CAPVAXIVE 65 ug/.5mL?
The NDC (National Drug Code) for CAPVAXIVE 65 ug/.5mL is 0006-4347, listed by Merck Sharp & Dohme LLC.
Not medical advice. Always consult your doctor or pharmacist before making any medication decisions.
Data from openFDA · Public domain (CC0 1.0)